HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Joinn Laboratories - The Future Performance Is Worth Looking Forward To

Innovent Biologics (1801 HK) - Have the Genes to Become a Big Pharma

China Healthcare Weekly (Feb.19) - VBP on Biosimilar Drugs, Poor Performance of Healthcare Sector

JD Health (京东健康) Pre-IPO - Assumptions and Valuations

Insights on China Healthcare Policy: New Intensive Procurement Policy for High-Value Medical Devices

Insights On China Healthcare Policy - 4+7: New Volume-Based Purchasing Policy

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

Joinn Laboratories China  Lt / Equity Bottom-Up

<a href="https://www.smartkarma.com/entities/joinn-laboratories-china-co-a" target="_blank" data-smartkarma-citation="entities:28273:1" rel="noopener">Joinn Laboratories China Co-A (603127 CH)</a> recently released the third quarter report. The Q1-Q3 accumulated revenue was RMB632 million with a YoY growth rate of 81.2%. Net income attributed to shareholders in the first three quarters was RMB118 million, up 53.2% YoY. Q1-Q3 net income after deducting non-recurring gains and losses were RMB99 million, up 61.3% YoY. Q3 single quarter revenue, net income attributed to shareholders, and net income after deducting non-recurring gains and losses reached RMB234 million, RMB43 million and RMB34 million respectively, with YoY growth rates of 58.7%, 15.9% and 8.62% respectively. Performance was in line with expectations.<figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/171/396/original/image_43871431605317607684.png?1605317608" class="editor-image img-responsive" data-smartkarma-image-id="171396"></figure>Source: WIND

Joinn Laboratories China Co-A (603127 CH) recently released the third quarter report. The Q1-Q3 accumulated revenue was RMB632 million with a YoY growth rate of 81.2%. Net income attributed to shareholders in the first three quarters was RMB118 million, up 53.2% YoY. Q1-Q3 net income after deducting non-recurring gains and losses were RMB99 million, up 61.3% YoY. Q3 single quarter revenue, net income attributed to shareholders, and net income after deducting non-recurring gains and losses reached RMB234 million, RMB43 million and RMB34 million respectively, with YoY growth rates of 58.7%, 15.9% and 8.62% respectively. Performance was in line with expectations.Source: WIND

JOINN Laboratories - Q3 Performance in Line with Expectations; Promising Globalization After HK IPO